Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sumatriptan

FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sumatriptan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
FDA pharmacologic class
Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sumatriptan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

    NCT00963937 · start 2009-09-28

    Registered record
    Registry ID
    NCT00963937
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan 25 mg; Sumatriptan 50 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09-28
    Completion
    2010-12-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan 25 mg; Sumatriptan 50 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache

    NCT01791400 · start 2009-07

    Registered record
    Registry ID
    NCT01791400
    Conditions
    Migraine Disorders
    Interventions
    metoclopramide, injection,20mg, one time; Sumatriptan, injection, 6 mg, one time
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-11
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    Interventionmetoclopramide, injection,20mg, one time; Sumatriptan, injection, 6 mg, one time
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

    NCT00894556 · start 2009-06-10

    Registered record
    Registry ID
    NCT00894556
    Conditions
    Acute Migraine
    Interventions
    rizatriptan; Comparator: Placebo; Comparator: Sumatriptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06-10
    Completion
    2010-01-12
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Migraine
    Interventionrizatriptan; Comparator: Placebo; Comparator: Sumatriptan
    PhasePhase 3
    Registry statusCompleted

  • An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

    NCT00806546 · start 2009-02

    Registered record
    Registry ID
    NCT00806546
    Conditions
    Migraine Disorders
    Interventions
    NP101
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2011-05
    Enrolment
    514

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionNP101
    PhasePhase 3
    Registry statusCompleted

  • Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

    NCT00723983 · start 2008-11

    Registered record
    Registry ID
    NCT00723983
    Conditions
    Migraine Disorders
    Interventions
    Sumatriptan succinate; NP101 Study Patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionSumatriptan succinate; NP101 Study Patch
    PhasePhase 1
    Registry statusCompleted

  • Study in Participants With Acute Migraines Headaches

    NCT00804973 · start 2008-11

    Registered record
    Registry ID
    NCT00804973
    Conditions
    Migraine Headache
    Interventions
    LY2590443; Placebo injection; Sumatriptan; Placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-11
    Completion
    2009-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionLY2590443; Placebo injection; Sumatriptan; Placebo capsule
    PhasePhase 2
    Registry statusTerminated

  • Bioequivalence Study of Sumatriptan 100mg Tablets Under Fed Conditions

    NCT00872274 · start 2008-07

    Registered record
    Registry ID
    NCT00872274
    Conditions
    Healthy
    Interventions
    sumatriptan 100mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionsumatriptan 100mg
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Sumatriptan 100mg Tablets Under Fasting Conditions

    NCT00872924 · start 2008-07

    Registered record
    Registry ID
    NCT00872924
    Conditions
    Healthy
    Interventions
    sumatriptan 100mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionsumatriptan 100mg
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

    NCT00701389 · start 2007-11-20

    Registered record
    Registry ID
    NCT00701389
    Conditions
    Migraine Disorders
    Interventions
    telcagepant potassium; sumatriptan; sumatriptan placebo; telcagepant potassium placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11-20
    Completion
    2008-04-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    Interventiontelcagepant potassium; sumatriptan; sumatriptan placebo; telcagepant potassium placebo
    PhasePhase 1
    Registry statusCompleted

  • Comparing Naproxen to Sumatriptan for Emergency Headache Patients

    NCT00449787 · start 2007-03

    Registered record
    Registry ID
    NCT00449787
    Conditions
    Migraine; Tension-type Headache; Primary Headache Disorder
    Interventions
    Sumatriptan 100 mg; Naproxen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-03
    Completion
    2009-07
    Enrolment
    401

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Tension-type Headache; Primary Headache Disorder
    InterventionSumatriptan 100 mg; Naproxen
    PhasePhase 4
    Registry statusCompleted

  • A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

    NCT00382993 · start 2006-12

    Registered record
    Registry ID
    NCT00382993
    Conditions
    Migraine Disorders
    Interventions
    Placebo; Combination Product (sumatriptan succinate/naproxen sodium)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2007-11
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionPlacebo; Combination Product (sumatriptan succinate/naproxen sodium)
    PhasePhase 3
    Registry statusCompleted

  • TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

    NCT00385008 · start 2006-09-13

    Registered record
    Registry ID
    NCT00385008
    Conditions
    Migraine Disorders
    Interventions
    Combination Product (sumatriptan succinate / naproxen sodium); RELPAX(eletriptan) 40mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-09-13
    Completion
    2006-11-24
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionCombination Product (sumatriptan succinate / naproxen sodium); RELPAX(eletriptan) 40mg Tablet
    PhasePhase 3
    Registry statusCompleted

  • Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

    NCT00240617 · start 2005-10

    Registered record
    Registry ID
    NCT00240617
    Conditions
    Migraine Disorders
    Interventions
    sumatriptan succinate/naproxen sodium; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-06
    Enrolment
    623

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    Interventionsumatriptan succinate/naproxen sodium; placebo
    PhasePhase 3
    Registry statusCompleted

  • Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

    NCT00240630 · start 2005-10

    Registered record
    Registry ID
    NCT00240630
    Conditions
    Migraine Disorders; Migraine
    Interventions
    sumatriptan succinate/naproxen sodium; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-06
    Enrolment
    646

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders; Migraine
    Interventionsumatriptan succinate/naproxen sodium; placebo
    PhasePhase 3
    Registry statusCompleted

  • Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

    NCT00648466 · start 2004-11

    Registered record
    Registry ID
    NCT00648466
    Conditions
    Healthy
    Interventions
    Sumatriptan Succinate Tablets 100 mg; Imitrex® Tablets 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-11
    Completion
    2004-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSumatriptan Succinate Tablets 100 mg; Imitrex® Tablets 100 mg
    PhasePhase 1
    Registry statusCompleted